Results 101 to 110 of about 385,486 (311)

Opioids for the Treatment of Chronic Pain: Mistakes Made, Lessons Learned, and Future Directions

Anesthesia and Analgesia, 2017
An overreliance on opioids has impacted all types of pain management, making it undoubtedly a root cause of the “epidemic” of prescription opioid abuse in the United States.
J. Ballantyne
semanticscholar   +1 more source

An Expanding World of Novel Psychoactive Substances: Opioids

Frontiers in Psychiatry, 2017
The abuse of novel psychoactive substances (NPS) has been increasing dramatically worldwide since late 2000s. By the end of 2015, more than 560 NPS had been reported to the European Monitoring Centre for Drugs and Drug Addiction.
J. Zawilska
semanticscholar   +1 more source

Analysis of Novel Synthetic Opioids U-47700, U-50488 and Furanyl Fentanyl by LC-MS/MS in Postmortem Casework.

Journal of Analytical Toxicology, 2016
Following series of synthetic cannabinoid and synthetic cathinone derivatives, the illicit drug market has begun to see increased incidence of synthetic opioids including fentanyl and its derivatives, and other chemically unrelated opioid agonists ...
Amanda L A Mohr, Melissa Friscia, Donna M. Papsun, S. Kacinko, D. Buzby, B. Logan   +5 more
semanticscholar   +1 more source

Pilot findings on the real-world performance of xylazine test strips for drug residue testing and the importance of secondary testing methods

Drug and Alcohol Dependence Reports
Background: Xylazine is a sedative found increasingly in the illicit fentanyl supply that can cause hypotension, bradycardia, necrosis and death. This pilot examined the real-world performance of BTNX xylazine test strips (XTS) in drug residue samples ...
Erin Thompson, Jessica Tardif, Merci Ujeneza, Adina Badea, Traci C. Green, Haley McKee, Michelle McKenzie, Ju Nyeong Park   +7 more
doaj  

Morphine for the Treatment of Pain in Sickle Cell Disease

The Scientific World Journal, 2015
Pain is a hallmark of sickle cell disease (SCD) and its treatment remains challenging. Opioids are the major family of analgesics that are commonly used for treating severe pain.
Mihir Gupta, Lilian Msambichaka, Samir K. Ballas, Kalpna Gupta   +3 more
doaj   +1 more source

The dark side of opioids in pain management: basic science explains clinical observation

PAIN Reports, 2016
. Introduction:. In the past 2 decades, opioids have been used increasingly for the treatment of persistent pain, and doses have tended to creep up. As basic science elucidates mechanisms of pain and analgesia, the cross talk between central pain and ...
Cyril Rivat, Jane Ballantyne
doaj   +1 more source

Status and Rationality of Opioid Use in Lung Cancer Patients: A Single Center Retrospective Study

Chinese Journal of Lung Cancer, 2020
Background and objective Cancer pain affect the physical activity, psychological state and quality of life seriously, and even shortened the survival time of patients.
Wenjuan SUN, Yang HU, Wei ZUO, Bo ZHANG, Yan XU   +4 more
doaj   +1 more source

Opioids for low back pain

British medical journal, 2015
Back pain affects most adults, causes disability for some, and is a common reason for seeking healthcare. In the United States, opioid prescription for low back pain has increased, and opioids are now the most commonly prescribed drug class.
R. Deyo, M. Von Korff, David Duhrkoop
semanticscholar   +1 more source

Guideline for Prescribing Opioids for Chronic Pain

Journal of Pain & Palliative Care Pharmacotherapy, 2016
Improving the way opioids are prescribed through clinical practice guidelines can ensure patients have access to safer, more effective chronic pain treatment while reducing the number of people who misuse, abuse, or overdose from these drugs. The Centers
Centers for Disease Control and Prevention, Public
semanticscholar   +1 more source

Changes in Descending Pain Modulation During Anti–Tumor Necrosis Factor Therapy: A Prospective Study in Rheumatoid Arthritis and Spondyloarthritis

Arthritis &Rheumatology, EarlyView.
Objective In rheumatoid arthritis (RA) and spondyloarthritis (SpA), managing persistent pain remains challenging. Little is known regarding impaired pain pathways in these patients and the impact of biologic disease‐modifying antirheumatic drugs (bDMARDs).
Anne‐Priscille Trouvin, Arielle Simunek, Joël Coste, Terkia Medkour, Alice Combier, Lucile Poiroux, François Vidal, Sandrine Carvès, Didier Bouhassira, Serge Perrot   +9 more
wiley   +1 more source